Traws Pharma regains bid price compliance but remains at risk of delisting due to equity deficit

Traws Pharma, Inc.

Regained compliance with Nasdaq minimum bid price requirement as of Oct 29, 2024 after 10 consecutive business days above $1.00.
Company does not believe it satisfies Nasdaq stockholders' equity minimum of $2.5M; reported deficit of ~$(105.5)M as of June 30, 2024.
Will present a plan to regain equity compliance at a Nasdaq hearing scheduled for November 14, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.